Izinkinga zokukhathazeka ziyizifo zengqondo ezivame kakhulu e-US, ezithinta abantu abadala abangaba yizigidi ezingu-40 unyaka ngamunye, futhi naphezu kobuningi bemithi elwa nokukhathazeka etholakalayo, ukumelana nokwelashwa kwenzeka cishe ku-30% weziguli. Iziyaluyalu zokukhathazeka zinomthelela omkhulu wezomnotho ohlelweni lwezempilo lwase-US, okubiza phakathi kwamaRandi ayizigidi eziyizinkulungwane ezingu-42.3 kanye namaRandi ayizigidi eziyizinkulungwane ezingu-46.6 ngonyaka, okusho ukuthi kubalulekile ukuthola ezinye izindlela zokwelapha. Ngenhlanhla, ucwaningo olusha lwembula ukuthi ama-psychedelics angaba yimpendulo. Imiphumela yokuhlolwa komtholampilo ikhombisa ukuthi i-psilocybin, i-psychedelic enamandla, inemiphumela eqeda ukucindezeleka ezigulini ezinokucindezeleka futhi isebenza kangcono kune-escitalopram. Kunjalo, lokhu kumane kungenye yezifundo eziningi eziyimpumelelo ezibandakanya ukusetshenziswa kwezifo zengqondo njengokwelapha ukugula ngengqondo.
I-Cybin Inc igxile ekuthuthukiseni i-psychedelics ibe yimithi yokwelapha ngokuklama izinkundla zokutholwa kwezidakamizwa, izinhlelo ezintsha zokulethwa kwezidakamizwa, izindlela zokwakhiwa kwamanoveli kanye nemithi yokwelapha yezinkinga zempilo yengqondo.
Ngomhla ziyi-13 kuMbasa, uCybin wamemezela idatha ye-CYB004 ye-preclinical enhle evela ocwaningweni lwe-pharmacokinetic oluhlola i-molecule yayo ye-deuterated deuterated dimethyltryptamine (DMT), CYB004, elawulwa ngokuhogela. Ngokukhethekile, i-CYB004 ehogelwe ibonise izinzuzo ezibalulekile ngaphezu kwe-DMT efakwa emthanjeni nehogelwe, okuhlanganisa ubude besikhathi besenzo kanye nokutholakala kwe-bioavailability okuthuthukisiwe. Ucwaningo luphinde lwabonisa ukuthi i-CYB004 ehogeliwe ibe nokuqala okufanayo komphumela kanye nephrofayili yomthamo ku-IV DMT. Le datha ingase isekele amandla okuhogela njengohlelo olusebenzayo nolulawulwa kahle lokuletha abantu abanengqondo yokwelapha. I-Cybin okwamanje yenza i-CYB004 yokwelapha ukuphazamiseka kokukhathazeka. Le nkampani ilindele ukufaka isicelo sokuhlola ukuhlola ikota yesibili ka-2022 futhi iqale ucwaningo lokuhlola ngekota yesithathu.
“Ocwaningweni oluningi, i-DMT ikhombise ukuthi iyi-psychedelic ethembisayo nesebenzayo ekwelapheni izinkinga zempilo yengqondo. Kodwa-ke, imiphumela emibi eyaziwayo efana nokudideka nokukhathazeka kanye nendlela yakho yokuphatha iphazamise ngokomlando ukusetshenziswa nokutholakala kwayo. I-CYB004 ngokuhogela ingase ixazulule lezi zinselele futhi ekugcineni isekele indlela yomtholampilo eya phambili yalokhu kwelashwa okubalulekile. Njengengxenye yomgomo kaCybin jikelele wokudala izindlela zokwelapha ezisekelwe ku-psychedelic eziphephile nezisebenzayo, i-CYB004 ehogeliwe iyathuthukiswa ukuze inqobe ukulinganiselwa kwe-IV DMT futhi ibe inketho yokwelapha ebalulekile yokuphazamiseka kokukhathazeka ezigulini nakodokotela, "kusho uDoug Drysdale, i-CEO yakwaCybin. .
Ngomhla ziyisi-8 kuMbasa, uCybin wamemezela ukushicilelwa kwesicelo selungelo lobunikazi lamazwe ngamazwe esihlanganisa izindlela zokulethwa kokuhogela ama-molecule amaningi engqondo, okuqhubeka nokuqinisa isikhundla se-Cybin's intellectual property (IP). Uhlelo lokusebenza lwe-PCT luzovumela u-Cybin ukuthi afune ukuvikelwa kwe-IP kwezinhlobo eziningi ezihogeliwe zama-molecule e-psychedelic okwamanje asacwaningwayo futhi athuthukiswe yinkampani kanye namanye ama-molecule e-psychedelic angase athuthukiswe esikhathini esizayo.
"Ukushicilelwa kwalesi sicelo selungelo lobunikazi be-PCT kukhombisa ukuzibophezela kwethu okuqhubekayo ekutholeni nasekuthuthukiseni izinketho ezintsha zokwelapha ezisekelwe kwengqondo, ngaphezu kokuhlonza nokuhlanganisa izinhlelo zokulethwa okungenzeka zibe ngcono futhi ezilawulwa kahle nalaba abazobhapathizwa," kusho uDoug Drysdale. "Ngaphezu kwalokho, inqubekelaphambili yethu yokuvikela i-IP yezindlela ezihlukile zokulethwa kwe-psychedelic psychedelic iqondana ngokuqinile futhi isekela uhlelo lwethu lwamanje lwepayipi ye-CYB004 ye-DMT ekhishwe ngokuhogela, okuhloswe ngayo ukunqoba ezinye zezinselele ezaziwayo ze-DMT yomlomo ne-IV."
UCybin umemezele ngoMashi 31 ukuthi ucwaningo lwayo oluxhasiwe olusebenzisa ubuchwepheshe be-Kernel Flow yenze ukuvakasha kwayo kokuqala. Injongo eyinhloko yocwaningo ukuhlola ukuzizwisa kombambi qhaza egqoke i-Kernel Flow ngenkathi esesimweni sokwazi esishintshile ngemva kokuphathwa kwe-ketamine. Ababambiqhaza bazothola umthamo ophansi we-ketamine noma i-placebo ngenkathi begqoke i-Flow headset, efakwe izinzwa ze-hi-tech ukurekhoda umsebenzi wobuchopho futhi bazobika ulwazi lwabo besebenzisa imibuzo ehleliwe kanye nokuhlola okuqinisekisiwe phakathi nokuvakasha kocwaningo nasekulandeleni. Ucwaningo lwamasonto amane luzophinde luhlole ukusebenza kobuchopho ngaphambi nangemva kokuphatha ama-ejenti ocwaningo - umthamo ophansi we-ketamine noma i-placebo.
LOKHO ONGAKUTHATHE KULESI SIHLOKO:
- The company expects to file a regulatory filing for a pilot study in the second quarter of 2022 and to initiate the pilot study in the third quarter.
- As part of Cybin’s overall mission to create safe and effective psychedelic-based therapeutics, inhaled CYB004 is being developed to potentially overcome the limitations of IV DMT and become an important treatment option for anxiety disorders for patients and physicians,”.
- The main objective of the study is to evaluate a participant’s experience wearing Kernel Flow while in an altered state of consciousness following the administration of ketamine.
